Psilocybin Microdosing vs Macrodosing: Two Very Different Interventions

The public conversation about psilocybin microdosing and macrodosing often treats them as points on the same spectrum — a smaller version of the same experience. Neurobiologically and clinically they are closer to two different interventions, with different evidence bases, different indications, different screening requirements, and different risks. Anyone weighing the two needs to know which claims are supported by placebo-controlled trials and which are supported mainly by self-report before deciding what is appropriate for their situation.

A microdose is typically defined as roughly 5–10% of a full psychoactive dose — sub-perceptual, intended to produce subtle cognitive or affective shifts without the classical psychedelic experience. Common protocols space doses every third day, on the theory that continuous daily dosing produces rapid tolerance to the intended effects. The publicly reported subjective benefits — improved mood, sharper focus, more creative output — are strikingly consistent across surveys and diaries. What is far less consistent is what happens when the same claims are tested against an inert placebo under blinded conditions: several controlled trials have found that self-selected microdosers cannot reliably distinguish their microdose sessions from placebo, and that expectation effects account for a meaningful share of the benefit people report. That does not mean microdosing does nothing. It means the effect size measured against placebo is considerably smaller and more variable than uncontrolled self-report would suggest, and anyone deciding whether to microdose should weigh that gap honestly rather than relying on anecdote alone.

A full macrodose — typically 20–30+ mg dried psilocybin equivalent, or an equivalent psilocin dose — produces the classical psychedelic experience: dense 5-HT2A receptor agonism, marked disruption of default-mode-network connectivity, a potential mystical-type or ego-dissolution experience, and a documented downstream window of neuroplasticity that appears to persist for days to weeks after the session. This is the dose regimen used across the treatment-resistant depression trials, the alcohol-use-disorder trials, and the end-of-life distress research. The therapeutic signal in these trials does not appear to come from receptor engagement alone; it appears to come from the combination of the acute altered-state experience with structured psychological support before and after dosing — which is why every serious clinical protocol pairs the dosing session with preparation and integration rather than treating the molecule as sufficient on its own.

Functional imaging of the macrodose state shows marked disruption of default-mode-network connectivity and a measurable shift in whole-brain integration (Carhart-Harris et al., 2012), and this same disruption has been proposed as the mechanistic bridge to the clinical improvements observed on fMRI follow-up after treatment-resistant depression sessions (Carhart-Harris et al., 2017). Microdoses, by design, are sub-perceptual and do not reliably produce this level of network disruption, which is one plausible reason their measured clinical effect is smaller and more variable than the macrodose literature. A broader review of psychedelic-induced neural plasticity situates both dosing strategies on the same underlying biology but notes that the magnitude of plasticity signaling scales with dose and subjective intensity (Weiss et al., 2025) — consistent with preclinical work showing that psychedelics promote structural and functional neural plasticity in a dose-dependent manner (Ly et al., 2018).

A macrodose session is not simply "a bigger dose taken with more caution." Before any macrodose work at Sanctuary Tulum, guests complete psychiatric history review, cardiovascular screening, and a medication reconciliation, because certain conditions and concurrent medications materially change the risk profile. Concomitant use of antidepressants with classic psychedelics is an area that requires particular clinical judgment: pharmacokinetic interactions and receptor down-regulation from chronic SSRI use can blunt or unpredictably alter the acute effects of psilocybin (Tap, 2025), so medication tapering — where appropriate and medically supervised — is planned well before the dosing day rather than improvised on arrival. Microdosing carries a different but real set of monitoring gaps: because it is typically self-administered outside any clinical setting, there is rarely a screening step at all, which means undiagnosed cardiac risk factors or interacting medications go unassessed by design.

Our program is macrodose-based. We do not run microdose protocols as a primary intervention, because our guests typically arrive with a defined and often severe clinical picture — treatment-resistant depression, PTSD, addiction, benzodiazepine dependence, chronic anxiety — that the trial evidence supports treating with full-dose sessions embedded in a structured residential protocol, not with a sub-perceptual regimen. Care is sequenced in three phases. Preparation comes first: medical clearance, psychiatric intake, and one-on-one work to set intention and identify what the session needs to address. The macrodose session itself follows, delivered under continuous clinical supervision in a controlled setting rather than as an isolated event. Integration comes after — structured one-on-one sessions in the days that follow to translate the acute experience into durable behavioral and psychological change, since the research consistently shows integration support is what converts a single altered-state experience into lasting benefit rather than a memorable but transient one. Microdosing may have a place in continued outpatient work for some guests after they leave, but it is discussed with and guided by a prescribing physician rather than self-managed. See our full psilocybin therapy program and the trial evidence review.

Macrodose work is appropriate for guests carrying a defined psychiatric diagnosis — major depression, treatment-resistant depression, alcohol use disorder, complex trauma — who can tolerate a full clinical screening and a structured multi-day protocol. It is not appropriate for guests with a personal or family history of psychosis, uncontrolled cardiovascular disease, or current use of medications that are contraindicated with 5-HT2A agonists, and every guest is screened for these before a session is scheduled. Microdosing is generally lower-acuity by design, but it is not risk-free, and it is not appropriate for self-directed use in people taking serotonergic medications or with unmanaged cardiac conditions, given theoretical concerns about chronic 5-HT2B agonism raised in the pharmacology literature. Explore our psilocybin vs SSRIs comparison for how these interactions are evaluated in practice.

Microdose risks include the valvulopathy concern associated with chronic 5-HT2B agonism in high-frequency, long-duration protocols — a theoretical risk flagged in the pharmacology literature that has not been fully characterized in humans and deserves more dedicated research before it can be dismissed or confirmed. Because microdosing is typically self-managed, this risk goes largely untracked in the population using it. Macrodose risks include acute psychological distress during the session, rare persisting perceptual changes afterward, and destabilization in guests with an undiagnosed psychotic-spectrum vulnerability that screening did not fully surface. Screening, a controlled setting, and trained clinical staff on hand reduce macrodose risk substantially compared with an unsupervised session; the risks of chronic, unsupervised microdosing are less well characterized precisely because the population using it is dispersed and outside any clinical monitoring structure, not because the risks are known to be smaller.

Guests arriving for macrodose work typically spend the first several days of a residential stay in preparation: medical clearance, a detailed psychiatric and medication history, and one-on-one sessions establishing what the work needs to accomplish. The dosing session itself takes place in a monitored setting with a clinician present throughout, informed by the same principles used in the ayahuasca and 5-MeO-DMT protocols elsewhere in our program. Integration follows over the subsequent days — dedicated one-on-one time to process what came up, connect it to the guest's history, and translate insight into a concrete plan for continuing care after departure. This is also where Sanctuary Tulum's continuing-care model comes in: guests who need ongoing outpatient support are connected with providers who can help decide, on a case-by-case and medically supervised basis, whether any continued low-dose or microdose protocol makes sense for them. Macrodose sessions are delivered inside a residential protocol — see our medically supervised psychedelic retreats and the wider holistic rehab program.